The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); EA Pharma (Inst); Eisai (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Minshan Chen
No Relationships to Disclose
 
Pierce K. H. Chow
Leadership - AVATAMED
Honoraria - AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; BTG; Guerbet; Ipsen; IQvia; MSD; New B Innovation; Omega Therapeutics; Oncosil; Perspectum Diagnostics; Roche; Sirtex Medical; Worrell
Consulting or Advisory Role - AUM Biosciences; Bayer; Bristol-Myers Squibb; BTG; Eisai; Genentech; Genentech; Guerbet; Ipsen; LEK; MSD; New B Innovation; Oncosil; Roche; Sirtex Medical; Soulbrain Holdings
Speakers' Bureau - AstraZeneca; Bayer; Perspectum Diagnostics; Roche; Sirtex Medical
Research Funding - AMiLi (Inst); Ipsen; IQvia; MiRXES; MSD; New B Innovation (Inst); Perspectum Diagnostics; Roche (Inst); Sirtex Medical (Inst); Stratificare
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Perspectum Diagnostics; Roche
 
Ahmed Omar Kaseb
Honoraria - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
 
Han Chu Lee
Research Funding - AstraZeneca; BMS Brazil; MSD; Roche
 
Adam C. Yopp
No Relationships to Disclose
 
Lars Becker
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Sairy Hernandez Painter
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Research Funding - Genentech
Patents, Royalties, Other Intellectual Property - HPK1 target as immunotherapy; HPK1 target as immunotherapy
Travel, Accommodations, Expenses - Genentech
 
Bruno Kovic
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Qinshu Lian
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Ning Ma
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Chun Wu
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Shukui Qin
No Relationships to Disclose
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche